United Therapeutics (NASDAQ:UTHR – Get Free Report) and Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership and profitability.
Analyst Ratings
This is a breakdown of recent ratings for United Therapeutics and Black Diamond Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| United Therapeutics | 1 | 3 | 12 | 0 | 2.69 |
| Black Diamond Therapeutics | 1 | 2 | 7 | 0 | 2.60 |
United Therapeutics presently has a consensus price target of $676.40, suggesting a potential upside of 14.42%. Black Diamond Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 648.30%. Given Black Diamond Therapeutics’ higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than United Therapeutics.
Earnings & Valuation
This table compares United Therapeutics and Black Diamond Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| United Therapeutics | $3.19 billion | 7.90 | $1.33 billion | $26.50 | 22.31 |
| Black Diamond Therapeutics | $70.00 million | 1.21 | $22.37 million | ($0.77) | -1.91 |
United Therapeutics has higher revenue and earnings than Black Diamond Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares United Therapeutics and Black Diamond Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| United Therapeutics | 38.61% | 19.18% | 17.07% |
| Black Diamond Therapeutics | N/A | -36.66% | -28.44% |
Risk & Volatility
United Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Black Diamond Therapeutics has a beta of 3.48, suggesting that its share price is 248% more volatile than the S&P 500.
Summary
United Therapeutics beats Black Diamond Therapeutics on 10 of the 14 factors compared between the two stocks.
About United Therapeutics
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for people with genetically defined cancers. The company uses its discovery platform to identify cancer-causing mutations and develop small-molecule therapies designed to target them. Its pipeline has included BDTX-1535, an investigational inhibitor designed to target certain EGFR alterations in cancers such as non-small cell lung cancer. The company’s candidates are in clinical development; it does not have an approved commercial product.
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
